The Effectiveness of Two Anti-HIV Treatments in HIV-Infected Patients
NCT ID: NCT00001057
Last Updated: 2021-11-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
105 participants
INTERVENTIONAL
1995-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Recent studies have shown that during the asymptomatic phase (clinical latency) of HIV infection, there is an extraordinarily large number of infected CD4+ lymphocytes and macrophages throughout the lymphoid system, both in latent and productive states. These findings support the belief that early intervention therapy with reverse transcriptase inhibitors could prolong the clinical latency period.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients are randomized to receive AZT alone, AZT plus ddI, or no therapy (placebo) daily for 48 weeks. Patients are followed at weeks 2, 4, and 8, and then every 8 weeks thereafter until week 48.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zidovudine
Didanosine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Allowed:
* Antibiotics for bacterial infections as clinically indicated.
* Recombinant erythropoietin (EPO) and G-CSF as clinically indicated for grade 3 or worse anemia and neutropenia, respectively.
* Antipyretics.
* Analgesics.
* Allergy medications.
* Oral contraceptives.
* Nonprescription medications such as vitamins or herbal therapies.
Concurrent Treatment:
Allowed:
* Radiation therapy to local lesion only.
* Acupuncture.
Patients must have:
* HIV seropositivity.
* CD4 count \>= 550 cells/mm3.
* No ARC or AIDS conditions by CDC criteria.
* Consent of parent or guardian if less than 18 years of age.
Exclusion Criteria
Patients with the following symptoms or conditions are excluded:
* Presence of factors predisposing to pancreatitis such as active alcoholism.
* Other medical conditions that would interfere with study compliance.
Concurrent Medication:
Excluded:
* Other antiretrovirals or systemic immunomodulators.
* Systemic corticosteroids.
* Systemic cytotoxic chemotherapy.
* Intravenous pentamidine.
Concurrent Treatment:
Excluded:
* Radiation therapy except to local lesion.
Patients with the following prior conditions are excluded:
* History of chronic diarrhea, defined as more than four loose or watery stools on average daily for the past month.
* History of grade 2 or worse peripheral neuropathy.
* History of pancreatitis.
* Bacterial infection requiring antibiotics within 14 days prior to study entry.
Prior Medication:
Excluded:
* Prior HIV therapy with antiretrovirals or systemic immunomodulators.
Prior Treatment:
Excluded within 2 weeks prior to study entry:
* Transfusion.
Active substance abuse or alcoholism.
13 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Erice A
Role: STUDY_CHAIR
Balfour H
Role: STUDY_CHAIR
Carey J
Role: STUDY_CHAIR
Henry K
Role: STUDY_CHAIR
Hasse A
Role: STUDY_CHAIR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hennepin County Med Clinic
Minneapolis, Minnesota, United States
Univ of Minnesota
Minneapolis, Minnesota, United States
St Paul Ramsey Med Ctr
Saint Paul, Minnesota, United States
Univ of Nebraska Med Ctr
Omaha, Nebraska, United States
Case Western Reserve Univ
Cleveland, Ohio, United States
Thomas Jefferson Univ Hosp
Philadelphia, Pennsylvania, United States
Univ of Texas Galveston
Galveston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11251
Identifier Type: REGISTRY
Identifier Source: secondary_id
ACTG 275
Identifier Type: -
Identifier Source: org_study_id